Oncology ImagingArchives
AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study
Oncology Imaging 5 min.
Breast cancer is the most prevalent malignancy and a leading cause of cancer-related mortality among women worldwide [1]. The human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in breast cancer, influencing both treatment response and disease progression [2,...
The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI
Oncology Imaging 5 min.
Breast cancer has emerged as the most prevalent malignant neoplasm globally and represents the second leading cause of cancer-related mortality among women worldwide [1]. Given the pronounced heterogeneity characteristic of breast cancer, the identification of optimal therapeutic strategies tailored...
Correlation of immunohistochemistry markers with textural characteristics derived from dual point F-18 fluorodeoxyglucose PET-CT in treatment naive locally advanced breast cancer patients.
Oncology Imaging 1 min.
Radiomics is an emerging field in medical imaging that leverages advanced computational algorithms to extract textural characteristics from medical images. It promises to transform breast cancer management by providing more accurate, reproducible, and noninvasive tools for clinicians, ultimately improving...
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)
Oncology Imaging 1 min.
Recent studies indicate that early changes on 2-deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) predict response to human epidermal growth factor receptor 2 (HER2)-directed therapy. EA1211/DIRECT is a multicenter, single-arm, primary imaging phase 2 study enrolling...
